Portola Pharma (PTLA) Tops Q3 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Portola Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update
November 9, 2015 4:06 PM ESTInitiated Rolling BLA submission to FDA for Andexanet alfa
--Conference Call Today at 4:30 p.m. ET--
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq: PTLA) today provided a corporate update and reported its financial results for the third quarter ended September 30, 2015.Â
We achieved a number of significant clinical, regulatory and manufacturing milestones over the past quarter, said William Lis, chief executive officer of Portola. We completed enrollment in the APEX study of betrixaban, our Fast Track-designated product. For andexanet alfa,... More
